{"schema_version":"secwatch.filing_event.v1","accession":"0001213900-25-126584","form_type":"8-K","ticker":"ADVB","cik":"0001941029","company_name":"Advanced Biomed Inc.","filed_at":"2025-12-30T23:59:59+00:00","discovered_at":"2026-05-14T18:02:41.114729+00:00","generated_at":"2026-05-16T12:01:46.022043+00:00","sec_items":["1.01","2.01","7.01","9.01"],"event_type":"m_and_a","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Advanced Biomed sells Hong Kong subsidiary for $23K; moves clinical trials to Taiwan","bullets":["Sold 100% of Advanced Biomed (HK) Limited and all IP of Shanghai Sglcell Biotech Co., Ltd. for US$23,000.","Transaction closed on December 23, 2025; board unanimously approved.","CEO cites evolving China regulatory requirements on clinical trials and data as reason for divestiture.","All clinical trials will now be centralized and conducted through the Taiwan subsidiary.","Buyer Wei Ha Hui is an unrelated third party."],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-25-126584","json":"https://secwatch.observer/filing/0001213900-25-126584.json","markdown":"https://secwatch.observer/filing/0001213900-25-126584.md","text":"https://secwatch.observer/filing/0001213900-25-126584.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1941029/000121390025126584/0001213900-25-126584-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1941029/000121390025126584/ea0271157-8k_advanced.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T12:01:46.022043+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"455481bf19be6b5ceef1310e650bfe7f47f229d3","claim":"Advanced Biomed Inc. completed a disposition involving Wei Ha Hui for US$23,000 (closed 2025-12-23).","evidence_excerpt":"ntered into an agreement (the “ Agreement ”) with an unrelated third party, Wei Ha Hui (the “ Buyer ”), pursuant to which the Company agreed to sell 100% of the issued and outstanding shares of Advanced Biomed (HK) Limited, a Hong Kong company","evidence_source":"SEC 8-K Item 2.01/5.01","evidence_url":"https://www.sec.gov/Archives/edgar/data/1941029/000121390025126584/0001213900-25-126584-index.htm","confidence":0.9,"family_label":"M&A Transactions","details":[{"label":"Action","value":"disposition"},{"label":"Counterparty","value":"Wei Ha Hui"},{"label":"Consideration","value":"US$23,000"},{"label":"Closing","value":"2025-12-23"}],"fact_type":"ma_transaction"},{"claim_id":"491cc694d8fafe622f413a6a0022066b025f3ad8","claim":"Advanced Biomed Inc. entered into Share Purchase Agreement with Wei Ha Hui valued at Purchase price of US$23,000 for 100% of Advanced Biomed (HK) Limited (effective 2025-12-23).","evidence_excerpt":"On December 23, 2025, Advanced Biomed Inc. (the “ Company ”) entered into an agreement (the “ Agreement ”) with an unrelated third party, Wei Ha Hui (the “ Buyer ”), pursuant to which the Company agreed to sell 100% of the issued and outstanding shares of Advanced Biomed (HK) Limited, a Hong Kong company and a wholly owned subsidiary of the Company (the “ Hong Kong Subsidiary ”), for an aggregate purchase price of US$23,000 based on a valuation report commissioned by the Company, subject to the terms and conditions set forth in the Agreement.","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1941029/000121390025126584/0001213900-25-126584-index.htm","confidence":0.95,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Agreement","value":"asset purchase"},{"label":"Counterparty","value":"Wei Ha Hui"},{"label":"Value","value":"Purchase price of US$23,000 for 100% of Advanced Biomed (HK) Limited"},{"label":"Effective","value":"2025-12-23"}],"fact_type":"material_agreement"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}